MISSION AND VISION
The eye offers a unique window into systemic health. By analyzing the retina, we can detect early signals of serious conditions, helping protect not only vision, but also patients’ health trajectory and long-term autonomy.
It refers to an AI-enhanced detection network that acts as a sentinel. It enables the identification of anomalies invisible to the naked eye during routine exams, ensuring constant, proactive monitoring at the population level.
Our technology enables fast, accurate, and decentralized screening. By identifying critical cases earlier, we help healthcare systems prioritize interventions and reduce specialist wait times.
SCIENTIFIC RIGOR AND CLINICAL ALLIANCE
Absolutely not. We believe in a clinical alliance: our technology supports practitioners by offering an unprecedented depth of insight. Final diagnosis and therapeutic decisions remain exclusively in the hands of the human expert.
Our algorithms are supported by more than 50 peer-reviewed scientific publications and conference presentations. They are trained on millions of images through collaborations with world-renowned hospital and academic centers.
Rigor is at the core of our data management practices. We strictly comply with Québec’s Law 25 and HIPAA standards, with secure hosting designed to ensure the full confidentiality and integrity of personal information.
GOVERNANCE
DIAGNOS Inc. is a public company listed on the TSX Venture Exchange under the symbol ADK (TSX-V: ADK).
All of our financial statements, management discussion and analysis reports, and annual filings are available in our Investors section or directly through the official SEDAR+ portal.
DIAGNOS is led by an experienced Board of Directors and executive team, supported by rigorous audit and governance committees to ensure full transparency toward our shareholders.
Our mission is inherently tied to social responsibility: we improve health equity through broader access to screening, while maintaining uncompromising AI ethics and sound corporate governance.
We aim to become the global standard in AI-assisted retinal vigilance. Our growth strategy is built on the international deployment of our infrastructure and the expansion of our detection capabilities to other chronic conditions.
